New interim data for the OPTIC phase 1 dose-ranging clinical trial of ADVM-022 intravitreal injection gene therapy for the treatment of wet age-related macular degeneration showed robust efficacy in each cohort, long-term durability in cohort 1 and the potential for fewer adverse events in cohort 3, according to a press release from Adverum Biotechnologies.
Three cohorts of patients have been treated with a single injection of ADVM-022. The first cohort of six participants was treated with a higher dose of 6 × 1011 vg per eye compared with six participants (Read more...)
Uncategorized